Formycon AG/€FYB
1D1W1MYTD1Y5YMAX
Capital at risk
About Formycon AG
Formycon AG is a biotechnology company based in Planegg, Germany, specializing in the development of biosimilar products. The company focuses primarily on creating biosimilar versions of top-selling biopharmaceuticals, addressing fields such as ophthalmology and immunology. Known for its significant expertise in protein and biopharmaceutical development, Formycon leverages its proprietary technical platform to advance its biosimilar pipeline. The company's strategic positioning includes partnerships with other pharmaceutical firms to co-develop and commercialize its biosimilar candidates. Formycon's competitive strength lies in its robust development capabilities and focus on high-growth therapeutic areas.
- Ticker
- €FYB
- Sector
- Health
- Primary listing
- XETRA
- Employees
- 196
- Headquarters
- Planegg, Germany
- Website
- www.formycon.com
Formycon AG Metrics
BasicAdvanced
€353M
-
-€1.42
0.72
-
Price and volume
Market cap
€353M
Beta
0.72
52-week high
€26.85
52-week low
€16.64
Average daily volume
4.7K
Financial strength
Current ratio
2.039
Quick ratio
1.42
Long term debt to equity
0.019
Total debt to equity
0.022
Profitability
EBITDA (TTM)
9.407
Gross margin (TTM)
22.81%
Net profit margin (TTM)
-41.04%
Operating margin (TTM)
-24.25%
Effective tax rate (TTM)
51.36%
Revenue per employee (TTM)
€310,000
Management effectiveness
Return on assets (TTM)
-1.27%
Return on equity (TTM)
-6.33%
Valuation
Price to revenue (TTM)
5.775
Price to book
0.92
Price to tangible book (TTM)
-12.8
Price to free cash flow (TTM)
-8.595
Free cash flow yield (TTM)
-11.63%
Free cash flow per share (TTM)
-2.329
Growth
Revenue change (TTM)
18.28%
Earnings per share change (TTM)
-85.19%
3-year revenue growth (CAGR)
-3.73%
10-year revenue growth (CAGR)
14.46%
3-year earnings per share growth (CAGR)
-19.54%
10-year earnings per share growth (CAGR)
19.72%
Bulls say / Bears say
Q1 2026 revenue more than doubled from €5.3 million to €13.1 million, reflecting strong commercial momentum across its biosimilar portfolio (Reuters)
Launched its FYB203 aflibercept biosimilar under the brands Ahzantive® and Baiama® in Germany, France, and Italy starting May 15, 2026, marking its first EU commercial roll-out (Reuters)
Settled patent disputes with Regeneron and Bayer via a settlement and license agreement, clearing the path for FYB203 launches across Europe, Latin America, and Asia-Pacific from May 2026 (Reuters)
Q1 2026 revenue growth was driven by one-off milestone payments for FYB202 and FYB206, underscoring reliance on non-recurring income streams (Reuters)
Despite top-line growth, Formycon reported an EBITDA loss of €1.7 million in Q1 2026, indicating ongoing unprofitability and high operating costs (Reuters)
Confirmed full-year guidance despite a significant revenue decline in the first nine months, reflecting challenges in sustaining growth momentum for existing biosimilars (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2026.
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.